Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036

Zhengguo Wu, J. Zhang, Wei Jiang, Can Huang, Wenfeng Xu, Jia‐Qiang Wu, Meirong JiangFrontiers in Public Health 2025 · DOI

Abstract

The dual burdens of varicella and herpes zoster in low-SDI regions and aging-driven herpes zoster resurgence in high-SDI areas necessitate targeted strategies. These include prioritizing pediatric varicella immunization and equitable vaccine distribution in developing nations while enhancing adult herpes zoster booster programs and surveillance in developed ones to meet WHO 2030 targets.

Introduction

The varicella-zoster virus (VZV) presents a complex public health challenge due to its unique lifecycle. Primary infection causes varicella (chickenpox), after which the virus remains latent in the nervous system, potentially reactivating decades later as herpes zoster (shingles). While effective vaccines exist for both conditions, global coverage remains highly uneven, creating a "dual burden" of disease.

This study analyzes the global burden of VZV from 1990 to 2021, examining how socioeconomic development—measured by the Socio-demographic Index (SDI)—influences outcomes. It also investigates the disruptive impact of the COVID-19 pandemic on routine immunization and provides predictive modeling through 2036.

Methods

Researchers utilized data from the Global Burden of Disease (GBD) 2021 study, synthesizing epidemiological information from 204 countries and territories. Supplemental data were sourced from the Institute for Health Metrics and Evaluation (IHME) and the WHO Global Health Observatory.

The analysis employed several statistical techniques:

  • Joinpoint Regression: To identify significant inflection points in disease burden trends, particularly around the 2019 pandemic onset.
  • Bayesian Age-Period-Cohort (BAPC) Model: To project future incidence rates up to 2036.
  • Frontier Analysis: To evaluate health management efficiency relative to SDI.
  • Decomposition Analysis: To distinguish between drivers of burden, such as population growth, aging, and epidemiological shifts.

Results

The study reveals a significant shift in the global VZV landscape over three decades. While total cases increased by 19%—rising from 72.8 million in 1990 to 86.7 million in 2021—the age-standardized incidence rate (ASIR) has remained relatively stable.

Table 1: Global incidence of VZV by region and SDI, 1990 vs 2021.

A major success has been the dramatic reduction in mortality. Global age-standardized mortality rates (ASMR) plummeted by 50%, and Disability-Adjusted Life Years (DALYs) dropped by 36.3%. However, stark inequalities persist; low-SDI regions still account for over 67% of all VZV-related deaths and DALYs, largely due to limited vaccine access and weaker primary care infrastructure.

Table 2: Global mortality and death rates for VZV, 1990 vs 2021.

The year 2019 emerged as a critical inflection point. The COVID-19 pandemic disrupted routine pediatric vaccination and adult booster programs, leading to a "collateral" surge in VZV cases in many regions. Future projections using the BAPC model suggest a gradual decline in ASIR for both sexes by 2036, though females are projected to maintain a slightly higher incidence (1.1%) than males.

Discussion

The findings highlight a "U-shaped" burden: children under five experience the highest incidence of chickenpox, while adults over 45 face the greatest risk of mortality and disability from shingles. An "SDI Paradox" is also evident; high-SDI nations are seeing a resurgence in VZV burden driven by immunosenescence in aging populations. Frontier analysis indicates that even advanced health systems, such as those in the UK and Norway, are struggling to optimally manage the shingles burden in the elderly.

Limitations

The study relies on GBD estimates which, in low-SDI regions, often depend on clinical diagnosis rather than PCR confirmation, potentially leading to underreporting. Furthermore, while a correlation between the pandemic and rising VZV cases is clear, definitive biological causality regarding COVID-19-induced reactivation requires further investigation.

Conclusion

To meet WHO 2030 targets, a "life-course" immunization strategy is essential. This involves prioritizing pediatric varicella vaccines in developing nations while aggressively expanding adult shingles booster programs in aging, high-income societies. Enhanced real-time surveillance is necessary to identify emerging epidemic signals and ensure equitable vaccine distribution.

Summary updated

Abstract

The dual burdens of varicella and herpes zoster in low-SDI regions and aging-driven herpes zoster resurgence in high-SDI areas necessitate targeted strategies. These include prioritizing pediatric varicella immunization and equitable vaccine distribution in developing nations while enhancing adult herpes zoster booster programs and surveillance in developed ones to meet WHO 2030 targets.
BibTeX
@inproceedings{wu2025global,
  author = {Zhengguo Wu and J. Zhang and Wei Jiang and Can Huang and Wenfeng Xu and Jia‐Qiang Wu and Meirong Jiang},
  title = {{Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036}},
  booktitle = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1654535},
}
Figure